Thyme Care Closes $95M Series C To Fuel Cancer Care Affordability
Thyme Care Closes $95M Series C To Fuel Cancer Care Affordability
-
New financing paves the path to profitability as Thyme Care mainstreams value-based cancer care; capital injection will support the anticipated broad rollout of national health plan coverage, power provider growth in new regions, and expand its reach to more patients in need
- Thyme Care challenges inefficiencies and waste in today's fee-for-service environment through 24/7 virtual care navigation, deep technology and data insights, and groundbreaking oncologist-led therapeutic interventions
- By harnessing relationships with oncology practices, primary care groups, and health plans, Thyme Care uniquely assumes two-sided financial risk to align payment incentives with care quality, while delivering an unparalleled patient experience
- 新融資爲Thyme Care通向盈利鋪平道路,主流的基於價值的癌症護理;注資將支持預計的全國醫療計劃覆蓋範圍的廣泛推出,爲新區域供應商提供增長,擴大其對更多需要患者的覆蓋範圍。
- Thyme Care通過全天候的虛擬護理導航,深入的技術和數據洞察以及開創性的腫瘤學家領導的治療干預,挑戰當今的按服務收費環境中的低效和浪費。
- 通過與腫瘤學實踐、初級護理組和保險計劃的關係,Thyme Care獨特地承擔了雙邊的金融風險,以協調支付激勵和護理質量,並提供無與倫比的患者體驗。
NASHVILLE, Tenn., July 16, 2024 /PRNewswire/ -- Thyme Care, the leading value-based cancer care enabler, today announced the close of a $95M capital raise. With $55M in equity funding, Thyme Care welcomes new investor Concord Health Partners with participation from all existing investors, including CVS Health Ventures, Town Hall Ventures, a16z Bio + Health, AlleyCorp, Echo Health Ventures, Frist Cressey Ventures, and Foresite Capital. Banc of California will provide an additional $40M in debt financing, bringing Thyme Care's total amount raised to date to $178M.
田納西州納什維爾,2024年7月16日/ PRNewswire / - 領先的基於價值的癌症護理啓用者Thyme Care今天宣佈完成了9500萬美元的資本籌集。 Thyme Care以5500萬美元的股本融資爲支持,歡迎新投資者Concord Health Partners並參與所有現有投資者,包括CVS Health Ventures,Town Hall Ventures,a16z Bio + Health,AlleyCorp,Echo Health Ventures,Frist Cressey Ventures和Foresite Capital。 Banc of California將提供額外的4000萬美元的負債融資,將Thyme Care籌集的總額提高到1.78億美元。
The cancer care ecosystem is nearing a financial breaking point, with drug costs accounting for up to 70% of the total cost of care and many life-saving cancer therapies costing upwards of $200,000 per year. Meanwhile, the experience of cancer care varies widely based on an individual's location, access to care, and ability to navigate the healthcare system. Many patients, particularly those already facing socio-economic barriers, experience gaps in support, financial toxicity, and a lack of coordination between visits.
癌症護理生態系統正接近財務破產邊緣,藥物成本佔總護理成本的70%,許多挽救生命的癌症療法的成本達到每年20萬美元以上。同時,癌症護理的體驗根據個人所在的位置、護理訪問權和導航醫療保健系統的能力而有很大的差異。許多患者,特別是那些已經面臨社會經濟壁壘的患者,經歷了對支持的差距、財務毒性和訪問之間的缺乏協調。
Thyme Care's suite of services, including its 24/7 specialized cancer care navigation services, robust technology and data insights, and provider-led therapeutic interventions enable a more seamless patient experience and drive sustainability across the ecosystem. Its core navigation services, including interventions to minimize acute care utilization and increase access to social services, show a $594 reduction in total costs per month for navigated patients compared to a control group. Through Thyme Care's Medicare Advantage and commercial payer agreements, as well as its collaborations in CMS's Enhancing Oncology Model (EOM), Thyme Care assumes financial responsibility for oncology populations at scale to reduce the total cost of care and improve outcomes and experience.
Thyme Care的服務套件包括24/7專業的癌症護理導航服務、強大的技術和數據洞察以及提供者領導的治療干預,使患者體驗更加無縫,推動整個生態系統的可持續性。其核心導航服務,包括最小化急性護理利用和增加社會服務訪問的干預,顯示針對被引導患者的總成本每月比對照組減少594美元。通過Thyme Care的醫療保險優勢和商業付款協議,以及其在CMS的Enhancing Oncology Model(EOM)中的合作,Thyme Care承擔規模化的腫瘤學人口的財務責任,以降低總護理成本並提高成果和體驗。
"Thyme Care's ability to enhance patient outcomes and reduce the total cost of care is directly aligned with our mission at Concord to support best-in-class companies with solutions that improve quality, increase access, and reduce cost of care," said James Olsen, founder and managing partner at Concord. "Their provider-led interventions targeting ballooning oncologic drug spend and acute care utilization highlight their unique approach to system-wide affordability, and their deep partnerships in cancer care mark their proven success. We look forward to partnering with Robin, Bobby, Brad, and the rest of the Thyme Care team to help the company scale in a market where its differentiated solution can so greatly impact cost and quality."
"Thyme Care提高患者成果並降低總護理成本的能力與我們在康科德(Concord)的使命直接對齊,即支持最佳的公司,提供可以改善質量,提高訪問和降低護理成本的解決方案,"說Concord創始人和管理合夥人詹姆斯奧爾森(James Olsen)。"他們的提供者領導的干預針對腫瘤學藥品花費和急性護理利用不斷膨脹突出了他們的獨特方法,以提高系統範圍內的可負擔性,並且他們在癌症護理方面的深入合作標誌着他們的已經取得了成功。我們期待着與Robin、Bobby、Brad和Thyme Care團隊的其餘成員合作,以幫助該公司在其差異化解決方案可以極大地影響成本和質量的市場上擴大規模。"
To reduce oncologic drug spend across the cancer care system, Thyme Care has operationalized provider-led pharmacy intervention techniques, including drug waste minimization protocols, clinically equivalent drug substitutions, and more. Over the past year, Thyme Care has rapidly expanded its Thyme Care Oncology Partner (TCOP) partnerships to spearhead value-based cancer care. By operating as an extension of the practice, Thyme Care deploys virtual care delivery services and analytic capabilities to reduce administrative burden, unlock practice efficiency, and enable success in new payment arrangements.
爲了降低整個癌症護理系統的腫瘤學藥品花費,Thyme Care已經運營了提供者領導的藥房干預技術,包括藥物浪費最小化協議、臨床等效藥物替代等。在過去的一年中,Thyme Care迅速擴大了其Thyme Care Oncology Partner(TCOP)夥伴關係,以推動基於價值的癌症護理。通過作爲實踐的延伸,Thyme Care部署虛擬護理交付服務和分析能力,以減少行政負擔,提高實踐效率,並在新的付款安排中取得成功。
"Our latest funding is a testament to the dedication and expertise of our incredible team, whose relentless efforts drive our mission to transform the cancer care experience forward," said Robin Shah, Thyme Care co-founder and chief executive officer. "We are profoundly grateful for the unwavering support and collaboration of investors, providers, and payer partners, whose commitment makes Thyme Care's unique, provider-centered approach possible. Together, we are reshaping the landscape of oncology, ensuring better care and affordability for all."
"我們最新的資金籌集證明了我們的團隊的奉獻精神和專業知識,他們不懈的努力推動了我們的使命,將癌症護理的體驗轉型向前推進,"Thyme Care聯合創始人兼首席執行官Robin Shah說。"我們對投資者、提供者和支付方合作支持和協作深表感謝,他們的承諾使Thyme Care的獨特的以提供者爲中心的方法成爲可能。在一起,我們正在重塑腫瘤學的格局,確保更好的護理和負擔得起的價格,到達所有人。"
Thyme Care will use the new funds to grow and scale the business by expanding into new markets, investing in its existing oncology, primary care, and health plan partnerships, and deepening its clinical value-based care model. Thyme Care is actively managing more than half-billion dollars in medical spend across its risk-based contracts and is on pace to more than triple that number within the next year. In addition, the company has more than doubled its oncology partnerships over the past six months, with active plans to expand across the United States through additional contracts with health plans, employers, and risk-bearing primary care groups.
Thyme Care將利用新資金通過進入新市場、投資現有的腫瘤學、初級保健和醫療保險夥伴關係,以及加深其臨床價值爲基礎的護理模型,擴大業務規模和增長。Thyme Care正在積極管理超過5億美元的醫療支出風險合同,並計劃在未來一年內將這個數字增加到3倍以上。此外,公司在過去六個月中已將其腫瘤學合作伙伴關係增加了一倍以上,並有積極計劃通過與醫療保險公司、僱主和承擔風險的初級保健組織的其他合同來擴展其覆蓋範圍。
"Cancer is a complex and costly disease, but we're committed to supporting both patients and providers to improve the care experience," said Vijay Patel, managing partner, CVS Health Ventures. "Thyme Care's provider-focused approach is transforming care delivery and supporting alternative payment models, and we're excited about all the ways we can leverage our strategic expertise to continue their growth. We look forward to helping them scale these critical services to make cancer care more affordable and accessible."
"癌症是一種複雜且昂貴的疾病,但我們致力於支持患者和提供者改善護理體驗,"CVS Health Ventures的管理合夥人Vijay Patel說。"Thyme Care的以提供者爲重點的方法正在改變護理交付並支持替代付款模型。我們對利用我們的戰略專業知識,繼續擴大其增長的各種方式感到興奮。我們期待着幫助他們將這些重要服務擴展到所有人,以使癌症護理更加負擔得起和易於訪問。"
About Thyme Care
Thyme Care is the leading value-based care enabler, collaborating with payers and providers to transform the experience and outcomes for individuals living with cancer. The company partners with health plans, employers and risk-bearing providers to assume accountability for enhanced care quality, improved health outcomes, and reduced total cost of care. Thyme Care's approach combines a technology-enabled Care Team and seamless integration with more than 800 oncologists in Thyme Care Oncology Partners, creating a hybrid collaborative care model that guides and supports the entire patient journey. Thyme Care empowers oncologists nationwide through purpose-built tech, advanced data analytics, and virtual patient engagement, driving better care and outcomes in value-based arrangements. Thyme Care is a founding member of CancerX, and is backed by leading investors. To learn more about how Thyme Care is enabling the shift to value-based care in oncology, visit .
關於Thyme Care
Thyme Care是領先的基於價值的護理支持者,與支付者和提供者合作,改變患有癌症的人的體驗和結果。該公司與醫療保險公司、僱主和承擔風險的提供者合作,承擔責任以提高護理質量、改善健康結局並降低總護理成本。 Thyme Care的方法結合了技術支持的護理團隊和與Thyme Care Oncology Partners的800多名腫瘤學家的無縫融合,創建了一個混合協作護理模型,引導並支持整個患者旅程。 Thyme Care通過專爲建立目的而建的技術、先進的數據分析和虛擬患者參與來賦權全國的腫瘤學家,以在基於價值的安排中驅動更好的護理和成果。 Thyme Care是CancerX的創始成員,得到了頂尖投資者的支持。要了解有關Thyme Care如何在腫瘤學領域推動基於價值的護理轉型的更多信息,請訪問。
Contact
Kimberly Dreisinger
Thyme Care Communications
[email protected]
聯繫人
金伯利·德萊辛格
Thyme Care通訊
[email protected]
SOURCE Thyme Care
資源:Thyme Care